• About us
• Contact

Advertisement

Organisation › Details

Oxford Genetics Ltd. (Oxgene)

Oxford Genetics, headquarted in Oxford, UK, is a leading synthetic biology company dedicated to the creation of biology-based technologies to aid in the discovery and development of biologics, cell and gene therapies. Founded in 2011, the company has experience in DNA design for the optimisation of protein expression, improved viral delivery systems and cell line engineering. *

 

	Start	2011-01-01 established
	Industry	synthetic biotechnology
	Industry 2	gene therapy
	Person	Cawood, Ryan (Oxford Genetics 2011– CEO + Founder)
	Person 2	Brooks, Paul (CN Innovations 202212– CEO joined as CBO 5/22 before Horizon Discovery + Oxford Genetics + Sigma-Aldrich)
	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Robert Robinson Avenue Oxford Science Park, Medawar Centre
	City	OX4 4HG Oxford, Oxfordshire
	Tel	+44-1865-415-107
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for WuXi PharmaTech (Group)

• [1] Metrion Biosciences Ltd.. (7/26/21). "Press Release: Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development". Cambridge....
• [2] Oxford Genetics Ltd.. (3/2/21). "Press Release: WuXi AppTec Completes Acquisition of Oxgene to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers". Philadeliphia, PA & Oxford....
• [3] Genomics Medicine Ireland Ltd.. (8/12/19). "Press Release: Genomics Medicine Ireland Announces Strategic Advisory Board"....
• [4] Sphere Fluidics Ltd.. (2/18/19). "Press Release: Oxford Genetics and Sphere Fluidics Announce a Multi-partner Collaboration to Expedite the Development of Automated Microfluidic Systems for Rapid and High-throughput Gene Editing in Mammalian Cell Lines"....
• [5] Oxford BioTherapeutics Ltd.. (12/11/18). "Press Release: Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody Platform for Five Bispecific Antibody Programs for up to $450 Million". Shanghai & Oxford....
• [6] Genomics Medicine Ireland Ltd.. (11/27/18). "Press Release: $400 Million Investment Programme Positions Ireland for Global Leadership in Genomic Research and Advanced Life Sciences"....
• [7] Genomics Medicine Ireland Ltd.. (11/7/18). "Press Release: GMI Genomics Centre Awarded CAP-Accreditation"....
• [8] Genomics Medicine Ireland Ltd.. (11/6/18). "Press Release: GMI Appoints Dr. Anne Jones as CEO"....
• [9] Oxford Genetics Ltd.. (9/20/18). "Press Release: Oxford Genetics Extends Its CRISPR Gene Editing Technology License Agreement from ERS Genomics to Support Its Growth Internationally". Oxford....
• [10] Genomics Medicine Ireland Ltd.. (8/30/18). "Press Release: Genomics Medicine Ireland and University of Cambridge Announce Multiple Sclerosis Research Collaboration". Dublin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.